Variations in the lipid profile of patients with chronic renal failure, treated with folic acid.
Dyslipidemia and increases in plasma homocysteine usually occur at end-stage renal disease; both are recognized as risk factors for atherosclerosis. Folate administration reduces homocysteine concentration. In this study we determined the effect of a high dose of folic acid (40 mg intravenous injection three times a week) on plasma and red blood cell lipid profiles in twelve chronic renal failure patients on regular hemodialysis. Fasting blood samples were taken at the beginning of the study (baseline) and after 21, 42, and 64 days of treatment. Folic acid supplementation decreased plasma homocysteine. Plasma triglyceride levels decreased whereas polyunsaturated fatty acid values increased after 21 days; then they returned to baseline levels at the end of treatment. Total cholesterol and low-density lipoprotein (LDL) cholesterol were higher than those of the baseline during all the study, whereas high-density lipoprotein (HDL) cholesterol was reduced. In erythrocyte membranes, folic acid therapy enhanced cholesterol/phospholipid ratios and the fluorescence anisotropy of diphenyl-hexatriene. We conclude that large doses of folic acid produce a favorable effect, reducing plasma homocysteine levels and protecting patients from atherosclerosis. However, as this therapy induces significant alterations in both plasma and erythrocyte membrane lipid profiles, plasma lipid values should be controlled throughout the treatment of patients with renal failure.
de Gómez Dumm
Nelva T
NT
Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP-CONICET-UNLP), Universidad Nacional de La Plata, 60 y 120, 1900, La Plata, Argentina. tacconi@atlas.med.unlp.edu.ar
Giammona
Ana M
AM
Touceda
Luis A
LA
D001161:Arteriosclerosis / Q000097:blood / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004912:Erythrocytes / Q000737:chemistry; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D006397:Hematinics / Q000008:administration & dosage / Q000627:therapeutic use*; D006710:Homocysteine / Q000097:blood* / Q000187:drug effects; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications / Q000517:prevention & control; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006397:Hematinics; D008055:Lipids; D014280:Triglycerides; D006710:Homocysteine; D005492:Folic Acid; D002784:Cholesterol